A Novel Mutation in the TSEN2 Gene Among Two Iranian Families with Pontocerebellar Hypoplasia Type 2B

Atefeh Khoshnevisan¹, Mohammad Shafiei¹, *, JavadMohammadiasl², Seyed Javad Mowla³ and Shahram Nasiri⁴

¹Department of Biology, Faculty of Sciences, Shahid Chamran University of Ahvaz, Ahvaz, Iran
²Department of Medical Genetics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
³Molecular Genetics Department, Faculty of Biological Sciences, Tarbiat Modares University, Tehran, Iran
⁴Department of Pediatrics, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran

*Corresponding author: Department of Biology, Faculty of Sciences, Shahid Chamran University of Ahvaz, Ahvaz, Iran. Email: shafieimoh@yahoo.com

Received 2022 July 11; Revised 2022 August 09; Accepted 2022 August 10.

Abstract

Background: Pontocerebellar hypoplasia is an autosomal recessive and neurodegenerative disorder divided into sixteen subtypes. Pontocerebellar hypoplasia type 2B shows microcephaly, combined with epilepsy extrapyramidal dyskinesia and chorea due to different homozygous or compound heterozygous pathogenic mutations in the TSEN2 gene.

Objectives: This study aimed to find the mutation responsible for pontocerebellar hypoplasia in two families with similar patients using the next-generation sequencing technique.

Methods: Whole exome sequencing (WES) was performed for two individuals in families with microcephaly and developmental delay. A novel mutation was confirmed by Sanger sequencing and segregation analysis. Pathogenicity and the effect of mutation were investigated using different bioinformatics analyses.

Results: WES showed a novel, potential pathogenic mutation in TSEN2 (p.R350Q: c.1049G>A). Sanger sequencing verified that both individuals were homozygote and that their parents were heterozygote for this variant.

Conclusions: Our data can help enhance knowledge about the role of the TSEN2 gene in pontocerebellar hypoplasia. Also, our results can extend the list of mutations responsible for PCH2B and help find the correlation between the genotypes and phenotypes for this disorder.

Keywords: Pontocerebellar Hypoplasia, TSEN2, Novel Mutation, Whole Exome Sequencing

1. Background

Pontocerebellar hypoplasia (PCH) is a group of neurodegenerative disorders with an autosomal recessive inheritance pattern. Such diseases have a prenatal onset and primarily affect the growth and survival of the neurons in the cerebellar cortex. This event leads to microcephaly, seizures, cerebellar hypoplasia, and a significant delay in motor and cognitive development (1-3).

Recent classification divided PCH into sixteen subtypes based on the OMIM database. Although PCH is a severe developmental disorder, clinical and neurological differences may exist between and within different subtypes. For example, PCH1 is usually characterized by the additional dysfunction of motor neurons in the spinal cord, which resembles infantile spinal muscular atrophy. PCH type 2 represents progressive microcephaly along with epilepsy, severe chorea, extrapyramidal dyskinesia, and normal spinal cord signs (4).

Different genes are associated with each subtype of PCH, which may broaden the clinical features. For example, the VRK1, EXOSC3, EXOSC8, EXOSC9, SLC25A46, and EXOSC1 genes have been reported for PCH1. Also, the TSEN54, TSEN2, TSEN34, and SEPSECS genes have been associated with different subtypes of PCH2. The PCH2 subtypes are classified based on the order of identifying responsible genes. One subtype of PCH2 is PCH2B (OMIM: 612389), which occurs by the homozygous or compound heterozygous mutations in the TSEN2 gene (4).

The TSEN2 gene encodes a heterotetrameric enzyme as a subunit of the tRNA splicing endonuclease complex involved in the maturation of tRNA molecules. Other subunits of this complex are encoded by the TSEN15, TSEN34, and TSEN54 genes (4-6). The functional complex catalyzes the tRNA processing through the intron removal, a process required for the proper protein synthesis for cell growth and division (7).
Due to several different genes and the overlapping clinical features of PCH, whole exome sequencing (WES) is considered a useful method for detecting variants responsible for diseases. Although targeted gene panels have been developed, they are at risk of being outdated due to the increased rate of new gene discoveries (8). Thus, WES seems to be a suitable method of detecting the genetic cause of pontocerebellar hypoplasia.

In the current study, we reported two patients with similar phenotypes attributed to pontocerebellar hypoplasia. WES was used to find the genetic cause of the disorder in the patients’ families living in the province of Khuzestan, Iran. Our results showed that the families shared a common missense mutation in the TSEN2 gene.

2. Objectives

Our study aimed to find the genetic cause of a disorder in two patients from two families with cerebellar hypoplasia through WES, followed by in silico and segregation analyses.

3. Methods

3.1. Clinical Reports

The ethics committee of Shahid Chamran University of Ahvaz, Iran, approved the study (ethical code: EE/99.3.0239631/scu.ac). Two patients with undiagnosed developmental delay were referred for genetic testing. Both had some symptoms related to PCH, such as progressive microcephaly, cerebellar hypoplasia and atrophy, problems in movement, dystonia, and intellectual disability. Other features of dysmorphism were absent in them. Patient I was a 4-year-old boy with healthy consanguineous parents and a history of several deceased affected patients in the family. The patient had developmental delay, intellectual disability, and such movement disorders as dystonia and spasticity. The patient’s brain MRI demonstrated cerebellar atrophy, while his EEG showed no abnormal epileptic waves. Patient II was a 6-month-old male infant with healthy consanguineous parents. The patient had developmental delay, microcephaly, and hypotonia, according to his physical examination. Pedigrees of the two families are shown in Figure 1.

3.2. Karyotyping

Karyotyping was done for the patients according to the previous protocols to check for any chromosome anomalies in them (9, 10).

3.3. DNA Extraction

Blood tubes of 5 mL were collected from the patients and their available family members using EDTA as an anticoagulant. Genomic DNA was isolated using the salting out procedure and stored at -20°C. The DNA quantity was checked using the NanoDrop-1000 spectrophotometer (NanoDrop™ 2000 Spectrophotometer, Thermo Scientific™, USA), and its quality was examined by agarose gel electrophoresis.

3.4. Whole Exome Sequencing

WES for the two extracted DNA samples was done using the commercial service (Macrogen Inc., Seoul, Korea). The exome capture of DNA from the two probands was accomplished using the Agilent SureSelect Target Enrichment Kit (SureSelect_v6 Agilent USA), followed by paired-end sequencing on the Illumina HiSeq4000 system (Illumina Inc., San Diego, CA). FASTQ raw data files were converted to the BAM files format. Then, the Genome Analysis Toolkit (GATK) was applied for calling and filtering the variants. Finally, the variants were filtered based on parameters including frequency, genomic region, zygosity, protein effect, and correlation with the clinical features (11, 12).

3.5. In Silico Analysis of the Variants

Variants with minor allele frequency (MAF) \( \leq 0.01 \) were filtered for further analysis by applying different databases such as Exome Aggregation Consortium (ExAC), 1000 Genome Project, Genome Aggregation (gnomAD), and Iranome databases (13-16). Then, synonymous and intronic variants were filtered out. Also, heterozygous variants were excluded based on the consanguineous background of the two families. However, the intronic and heterozygous variants in the patients were investigated later. Different in silico tools, such as SIFT, FATHMM, Mutation Taster, Polyphen 2, and CADD, were applied to predict the pathogenicity of the variants. Finally, VarSome was checked to find the pathogenicity of the variants based on the American College of Medical Genetics and Genomics (ACMG) guidelines. The conservation of the desired sequence was investigated through the alignment of the region encompassing the mutation among different species by MultAlin (multalin.toulouse.inra.fr/multalin) (17, 18).

3.6. Bioinformatics Analysis of Protein Stability and Structure

The I-Mutant and Missense3D algorithms were used to predict the functional consequences of the mutation in protein. Changes in the stability of the mutant form of the protein were checked using I-Mutant. This tool, which uses the experimental data of ProTherm, can automatically predict protein stability changes due to mutations. Missense3D predicts the effect of missense mutation on the
structure of proteins. The 3D structure of the wild-type protein and the missense variant was derived from this web server.

3.7. Sanger Sequencing and the Segregation Analysis of the Variants

The selected candidate variant (TSEN2: p.R350Q:c.G1049A) was validated by Sanger sequencing in both family members to confirm the segregation of the variants in the families. The polymerase chain reaction (PCR) was performed using primers amplifying the region. The primers (listed in Table 1) were designed with Primer3. ABI BigDye Terminator v3.1 Cycle Sequencing Kit, ABI 3100, and 3500xL Dx Genetic Analyser (Applied Biosystems, Foster City, CA, USA) were used for Sanger sequencing.

4. Results

4.1. Clinical Findings

Both families were known to be consanguineous from the first cousin marriages (Figure 1). The affected members showed similar symptoms including developmental delay, intellectual disability, hypotonia, and microcephaly. After undergoing a detailed examination by the physicians, the patients were referred for genetic analysis through next-generation sequencing to find probable mutations responsible for the disease.

4.2. Karyotype Analysis

The karyotype study of 20 metaphases showed the "46, XY" normal males. There were no chromosomal changes in either of the patients.

4.3. Analysis of Whole Exome Sequencing Data

The WES data were analyzed for the probands of each family. The data showed that the "mean depth: coverage: total number of variants" was (90.9X/97%/291245) and (91.7X/93.5/287456) for patients I and II, respectively. The data were also filtered based on inheritance and allele frequency to identify homozygous pathogenic variants. Finally, WES revealed a novel missense mutation, p.R350Q:c.G1049A, in the TSEN2 gene. Previously known as rs775547616, the variant showed very low frequency in a normal population. Also, the analysis of 800 normal Iranian cases showed no homozygosity in the population (Iraome.ir). Different in silico tools showed that the variant was pathogenic and had destroying effects on the protein structure (Table 2). Also, the alignment at the mutation locus showed that the variant was in a highly conserved region.

4.4. The Effect of Mutation on Protein Stability and Structure

Analyzing the effects of mutation on protein using I-Mutant showed the decreased stability of the protein (shown in Table 3). Moreover, analyzing the protein structure through Missense3D showed structural damage in the mutant form (Figure 2). The result showed that this substitution replaced a buried charged residue (Arg) with an uncharged residue (Gln).

4.5. Sanger Sequencing and Segregation Analysis

The affected individuals, their parents, and the unaffected individuals from the two families were genotyped by Sanger sequencing. Sanger sequencing results confirmed that the mutation was inherited as homozygous in
Table 1. Specific Primers of TSEN2 Gene for Variant Verification by Sanger Sequencing

<table>
<thead>
<tr>
<th>Primer</th>
<th>Sequences</th>
<th>Size of PCR Product</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSEN2 Forward</td>
<td>5′-GACCTTCCTGCTAATGCTTGTCG-3′</td>
<td>480 bp</td>
</tr>
<tr>
<td>TSEN2 Reverse</td>
<td>5′-CTTCTTACAAACCATCAACACGGAC-3′</td>
<td></td>
</tr>
</tbody>
</table>

Table 2. In Silico Prediction of p.R350Q Mutation Pathogenicity in TSEN2

<table>
<thead>
<tr>
<th>Protein</th>
<th>Amino Acid Change</th>
<th>SIFT</th>
<th>Mutation Taster</th>
<th>MutPred</th>
</tr>
</thead>
<tbody>
<tr>
<td>TSEN2</td>
<td>R350Q</td>
<td>0</td>
<td>Damaging</td>
<td>Disease causing</td>
</tr>
</tbody>
</table>

Table 3. Analysis Result of Mutation Effect on Protein Stability from I-Mutant Website

<table>
<thead>
<tr>
<th>Position</th>
<th>WT</th>
<th>NEW</th>
<th>Stability</th>
<th>RI</th>
<th>pH</th>
<th>T</th>
</tr>
</thead>
<tbody>
<tr>
<td>350</td>
<td>R</td>
<td>Q</td>
<td>Decrease</td>
<td>8</td>
<td>7.0</td>
<td>25</td>
</tr>
</tbody>
</table>

Abbreviations: WT, amino acid in wild-type protein; NEW, new amino acid after mutation; RI, reliability index; T, temperature in Celsius degrees; pH: -log[H+].

Figure 2. Result of Missense prediction 3D structure of wild-type (A) and mutant variant (B) of TSEN2 protein (uniprot ID: Q8NCE0). Position 350 in wild-type (arginine) and mutant (glutamine) is shown in blue and red, respectively.

5. Discussion

*TSEN2* encodes one of the subunits in the heterotetrameric tRNA splicing endonuclease complex, which is fundamental for the normal processing of tRNAs. Different mutations in this gene have been associated with pontocerebellar hypoplasia type 2 (3, 19). A few mutations have already been recognized in patients with PCH2. The major findings of this disease include microcephaly, developmental delay, and movement problems (6). The TSEN2 gene is located at 3p25.2 and contains 12 exons (transcript ID: ENST00000284995.11) (20).

Up to now, different mutations have been reported in the *TSEN2* gene, causing PCH2B. In 2008, Budde et al. identified mutations in *TSENs*, including *TSEN2* Y309C, in the affected pontocerebellar hypoplasia (19). Bierhals et al. detected the novel missense mutation in *TSEN2* (p.G312R) (4). Also, Wang et al. reported compound heterozygosity for two pathogenic mutations in *TSEN2* (p.Glu302Lys and...
The mutations were associated with PCH type 2B, characterized by abnormalities in the cerebellum and brainstem with extrapyramidal dyskinesia, epilepsy, and progressive microcephaly (21).

In the present study, we found two patients with similar symptoms from two unrelated families in Ahvaz, Southwest Iran. The cases’ parents were both first-cousins. Therefore, WES was used to investigate the cause of genetic mutation in the cases in whom developmental delay, hypotonia, and microcephaly were evident. We conducted next-generation sequencing on both affected probands and then confirmed the variant with different in silico tools, Sanger sequencing, and segregation analysis. The WES analysis revealed a homozygous missense mutation (p.R350Q) in the exon 8 of the TSEN2 gene, associated with pontocerebellar hypoplasia type 2B. This missense mutation, located in a conserved region (Figure 4), was shown to disrupt the normal function of protein through different software.

Based on our bioinformatics analysis and survey of the normal population in different databases, TSEN2: R350Q can be considered the candidate pathogenic variant identified by WES.

Acknowledgments

The authors thank the staff at Shahid Chamran University for supporting this study.
Figure 4. Multiple alignments revealing TSEN2 mutation in conserved domain of protein.

Footnotes

Authors’ Contribution: A. Kh. developed the original idea, performed the study, and wrote the manuscript. M. Sh. and J.M. conceived, designed, and supervised the study and revised the manuscript. S.J.M. re-evaluated the molecular data and advised and revised the manuscript. Sh. N. evaluated the clinical data.

Conflict of Interests: The authors declare that they have no conflicts of interest.

Ethical Approval: The ethics committee of Shahid Chamran University of Ahvaz approved the present study (Ethical code: EE/99.3.0239631/scu.ac).

Funding/Support: The grant number is “SCU.SB99.771”.

Informed Consent: Written informed consent was obtained.

References


